Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada
| العنوان: | Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada |
|---|---|
| المؤلفون: | Ameen, Mahreen, Meller, Stephan, Pinter, Andreas, Shear, Neil H., Soria, Angele |
| المساهمون: | Royal Free London NHS Foundation Trust, Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Frankfurt University Hospital, University of Toronto, Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) |
| المصدر: | Dermatology and Therapy Dermatology and Therapy, 2021, ⟨10.1007/s13555-021-00631-8⟩ |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Patients, Experiences, education, Dermatology, Disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Physicians, Medicine, 030212 general & internal medicine, Adverse effect, Intensive care medicine, Original Research, Atopic dermatitis, business.industry, medicine.disease, Dupilumab, Focus group, 3. Good health, Tolerability, Qualitative study, business, Psychosocial, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Biologic therapy |
| الوصف: | Introduction The Biologics in Atopic Dermatitis: Experiences & Learnings (BADEL) project aims to improve real-life understanding of how, where, and when biologics can play a role in the treatment of atopic dermatitis (AD) from the perspective of healthcare professionals (HCPs) and patients. Methods Individual experiences of 24 patients with moderate-to-severe AD and who had been treated with biologic therapy (dupilumab) for ≥ 3-6 months, and 20 HCPs with a sub-specialty interest in AD were collected by means of focus groups held in Canada, Germany, France, Italy and the United Kingdom. Dupilumab was the only biologic therapy available at the time of the study. Results Most patients had suffered from AD for many years, particularly from itch and psychosocial issues, with AD negatively impacting all aspects of their life. They had experienced a long treatment journey and seen many dermatologists, enduring treatment delays and failures. They had been prescribed various therapies without long-term success. Biologics provided symptom improvement, offering many patients a near-normal quality of life. Side effects, especially conjunctivitis, were the greatest drawback, and there were a few issues with incomplete or unreliable efficacy. HCPs agreed that biologic therapy for AD in the majority of patients demonstrated rapid onset, good efficacy and tolerability, and are a viable option in patients who had exhausted all other treatment options. However, those patients who failed to sufficiently respond or developed intolerable adverse effects, particularly ocular symptoms, require alternative therapeutic options. Conclusion Biologics can provide a near-normal quality of life for many patients with AD. Patients with AD who have failed conventional therapies should be offered all such novel therapies. Education and good patient-HCP communication will enable patients to manage their disease and treatment expectations. Patients and HCPs alike eagerly await alternative targeted therapies, which will offer greater choice and flexibility. |
| تدمد: | 2190-9172 2193-8210 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b39260fc2cbd2fe57bcd6c8c7194eb8Test https://doi.org/10.1007/s13555-021-00631-8Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5b39260fc2cbd2fe57bcd6c8c7194eb8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21909172 21938210 |
|---|